Back to articles

Two novel treatments show promise in preventive treatment of migraines


Two investigational monoclonal antibodies that target either the calcitonin gene-related peptide (CGRP) receptor (i.e., erenumab) or CGRP itself (i.e., fremanezumab) were shown to be effective for preventive treatment of migraines compared with placebo, according to results from two Phase III studies published in the New England Journal of Medicine.


Goadsby PJ, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–32.

Silberstein SD, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–21.

Hershey AD. CGRP—the next frontier for migraine. N Engl J Med. 2017;377(22):2190–1.